Peptide Education
Sexual Wellness & Melanocortin Biology
A clear, evidence-informed overview of sexual wellness biology, melanocortin pathways, and how mechanism, research quality, and whole-person context shape thoughtful clinical education.
Sexual Health Begins in the Brain—and Involves the Whole Body
Sexual function is often treated as if it were purely hormonal or purely vascular. In reality, the brain plays a major role in determining motivation, interest, attention, reward, and the body’s response to sexual cues.
The melanocortin system is especially interesting because it is one of the biological systems connecting the brain, behavior, energy regulation, pigmentation, and sexual response.
PT-141 / Bremelanotide • Melanotan I / Afamelanotide • Melanocortin Receptor BiologySexual Wellness Is a Whole-System Process
Sexual function involves coordination between the brain, nervous system, cardiovascular system, hormones, sensory pathways, emotional state, and interpersonal context.
A change in sexual desire or performance can therefore have many different causes. Effective evaluation begins by asking which part of the system may be interfering with normal sexual response.
Desire & Motivation
Sexual interest begins with central brain networks involved in motivation, reward, attention, emotional context, and attraction.
Brain & Nervous System
Neural pathways integrate sensory information, psychological state, autonomic responses, and sexual cues.
Circulation & Physical Arousal
Genital arousal depends partly on appropriate autonomic and vascular responses that increase local blood flow.
Hormonal Environment
Estrogen, testosterone, thyroid function, prolactin, menopause, medications, and metabolic health can influence sexual function.
Desire Is Not the Same as Performance
Someone can have intact physical function but low desire—or strong desire with impaired physical arousal. Understanding that difference is important when evaluating sexual-health concerns.
Understanding the Melanocortin System
Melanocortins are signaling peptides related to proopiomelanocortin (POMC) biology.
Their effects depend heavily on which melanocortin receptor is activated. Five receptor subtypes—MC1R through MC5R—are found in different tissues throughout the body.
Pigmentation
Strongly associated with melanocytes, eumelanin production, and skin pigmentation.
Adrenal Signaling
ACTH receptor involved primarily in adrenal corticosteroid signaling.
Central Regulation
Expressed in the nervous system and involved in aspects of energy and behavioral regulation.
Brain & Behavior
CNS receptor involved in appetite, energy regulation, reward, and pathways relevant to sexual behavior.
Peripheral Functions
Expressed in multiple tissues and involved in several peripheral and secretory functions.
Same Family ≠ Same Effect
Afamelanotide and bremelanotide both interact with melanocortin biology, but their clinical effects are very different because their receptor activity, formulation, and therapeutic development differ.
How Sexual Response Comes Together
Desire & Motivation
Sexual motivation begins within brain networks that assign attention, meaning, reward, and motivational significance to sexual cues.
Central Arousal
The brain integrates sensory input, emotional context, autonomic signaling, reward pathways, and attention.
Physical Response
Autonomic and vascular systems then contribute to genital blood flow, lubrication, erection, sensitivity, and physical arousal.
Experience & Satisfaction
Desire, physical response, comfort, emotional connection, cognition, relationship context, and expectations influence the overall sexual experience.
Melanocortin Peptides
PT-141 / Bremelanotide
Bremelanotide—often referred to by its development name PT-141—is a synthetic cyclic melanocortin receptor agonist.
Unlike medications that primarily act on genital blood flow, bremelanotide’s therapeutic development focuses on central nervous system pathways involved in sexual desire and arousal.
Melanotan I / Afamelanotide
Afamelanotide is a synthetic alpha-MSH analog developed from research historically associated with Melanotan I.
Its dominant clinical pathway is MC1R activation, which increases eumelanin production and pigmentation.
Melanotan I and SCENESSE Are Not Automatically Interchangeable
FDA-approved SCENESSE contains afamelanotide in a controlled-release subcutaneous implant. Research-market or compounded products called “Melanotan I” should not automatically be assumed to have the same formulation, delivery system, quality, pharmacokinetics, safety, or regulatory status.
Desire vs. Physical Arousal
Central Sexual Desire
Desire involves motivation, attention, reward, emotional state, sexual cues, and brain signaling.
PT-141 is unusual because its primary research and approved use focus on this central component of sexual function.
Peripheral Physical Arousal
Physical arousal depends more heavily on autonomic function, genital blood flow, vascular health, pelvic anatomy, sensory input, and tissue health.
These pathways may require a different evaluation and treatment strategy.
Why This Matters Clinically
Treating erection, lubrication, or genital blood flow does not necessarily correct low desire. Likewise, increasing sexual motivation does not automatically correct vascular, hormonal, pelvic, or neurological dysfunction.
What Has Bremelanotide Shown in Humans?
Phase III RECONNECT Trials
Two large randomized Phase III trials evaluated bremelanotide in premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Compared with placebo, bremelanotide produced statistically significant improvements in sexual desire and reductions in distress associated with low desire.
More Than 1,200 Participants
The combined Phase III program included more than 1,200 women, giving bremelanotide a much larger controlled human evidence base than many experimental peptides.
Earlier Male Research
Earlier experimental studies also reported erectile responses in healthy men and men with erectile dysfunction.
Those studies remain scientifically interesting, but Vyleesi is not FDA-approved for men or for erectile dysfunction.
FDA-Approved Sexual-Health Indication
Vyleesi is FDA approved for acquired, generalized HSDD in premenopausal women when the low desire causes meaningful distress or interpersonal difficulty and is not explained by a medical or psychiatric condition, relationship problem, medication, or other drug substance.
Limitations of the Approval
The FDA-approved product is not indicated for postmenopausal women, men, erectile dysfunction, or general enhancement of sexual performance.
PT-141 Safety & Important Considerations
Nausea
Nausea was the most common adverse reaction in Phase III trials and occurred in approximately 40% of Vyleesi-treated patients.
Flushing & Headache
Flushing, headache, vomiting, and injection-site reactions are among the other commonly reported adverse effects.
Blood Pressure
Bremelanotide can temporarily increase blood pressure and decrease heart rate after administration.
Pigmentation
Focal hyperpigmentation can occur because bremelanotide also has activity at MC1R.
Cardiovascular Contraindication
FDA-approved Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease.
Pregnancy & Medication Considerations
The approved labeling includes pregnancy precautions and notes that bremelanotide can slow gastric emptying, potentially affecting absorption of oral medications. Oral naltrexone has a specifically identified interaction.
Where Afamelanotide Fits
Afamelanotide demonstrates how dramatically receptor targeting can change the biological effects of a melanocortin peptide.
Whereas bremelanotide’s therapeutic development centers on central sexual-desire pathways, afamelanotide’s established clinical role centers on MC1R activation, eumelanin production, and photoprotection-related biology.
FDA-Approved Afamelanotide
SCENESSE is an FDA-approved afamelanotide implant indicated to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria.
Not an Approved Cosmetic Tanning or Sexual-Wellness Drug
The FDA-approved indication does not include cosmetic tanning, sexual desire enhancement, erectile dysfunction, or sexual performance.
The Bigger Picture
Changes in desire or sexual performance may reflect issues far outside the reproductive system.
Before reducing sexual wellness to a single peptide or hormone, it is worth evaluating the systems that influence sexual function every day.
Interested in Sexual Wellness?
Schedule a personalized wellness consultation to discuss sexual desire, hormonal health, medications, cardiovascular and metabolic factors, stress, symptoms, and available options.
Book a Wellness ConsultationSelected Scientific References
Two randomized Phase III RECONNECT trials evaluating bremelanotide for hypoactive sexual desire disorder.
View on PubMed →
Long-term safety and efficacy during the 52-week open-label extension of the RECONNECT program.
View on PubMed →
Early PT-141 research examining melanocortin pathways and erectile responses in men.
View on PubMed →
Current indication, contraindications, warnings, adverse reactions, and clinical pharmacology for bremelanotide.
View Current Label →
Human afamelanotide trials in erythropoietic protoporphyria.
View on PubMed →
FDA-approved afamelanotide implant indication and clinical information.
View FDA Label →
Discuss the Bigger Picture
If you want a more thoughtful conversation about sexual wellness, recovery, hormones, metabolism, and evidence-informed care, schedule a personalized consultation.